Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01404312 · ClinicalTrials.gov registry record · Phase 3
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT01404312 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,000 participants.
The verdict
NCT01404312, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of rifapentine (RPT) plus INH versus a standard 9-month regimen of INH in HIV-infected people who are at risk of developing active TB.
Interventions
- DRUG Isoniazid (INH)
- DRUG Rifapentine (RPT)
- DIETARY_SUPPLEMENT Pyridoxine (Vitamin B6)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2012-05-23 |
| Est. Completion | 2017-11-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01404312
The ClinicalTrials.gov registry entry for NCT01404312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Isoniazid (INH) is the first listed.
NCT01404312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01404312 about?
NCT01404312 is a clinical study titled "Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)". HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of rifapentine (RPT) plus INH versu...
What is the current status of trial NCT01404312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2012-05-23. Estimated completion is 2017-11-14.
What interventions are being tested in trial NCT01404312?
The interventions under investigation include: Isoniazid (INH) (DRUG), Rifapentine (RPT) (DRUG), Pyridoxine (Vitamin B6) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01404312?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.